Cite

HARVARD Citation

    Hashim, Y. et al. (2017). The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer. Journal of experimental & clinical cancer research. 36 (1), pp. 1-10. [Online]. 
  
Back to record